Alberta set to legalize hallucinogen-assisted therapies
Psilocybin is an active component of magic mushrooms that has shown particular promise in alleviating end-of-life distress in cancer patients.
Alberta is about to allow controlled access to psychedelic drugs for people undergoing therapy supervised by mental health professionals.
Hallucinogenic drugs include psilocybin, psilocin, MDMA, LSD, mescaline, DMT and ketamine.
Alberta is the first province to identify and understand that hallucinogens are the future area of treatment for so many Canadians struggling with mental health issues, says Dr. Robert Tanguay, co-chair of the Alberta Pain Strategy and co-lead of the Rapid Access to addiction medicine to Alberta Health Services (AHS) in a news release.
Alberta has the opportunity to be a leader in this area, he added.
Dr. change in the medical field begins with the recognition of the need to protect anyone who undergoes these treatments.
Access to drugs like LSD to treat some patients is a big step towards transforming mental health care, experts say.
The government has also introduced restrictions to limit access to these drugs and who can prescribe high-potency drugs to people with hard-to-treat opioid addictions, mental disorders including post-traumatic stress disorder (PTSD). ) and treatment-resistant depression.
These changes to the law will come into force in January 2023.
These changes are intended to protect the public, to ensure that patients receive high standards of care and to prevent drugs from being resold on the black market, according to the government.
The new measures, however, do not apply to clinical trials or treatment of people with non-psychiatric conditions, such as pain and cancer.
Clinics that wish to offer treatments using psychedelic drugs this type of treatment must be authorized and must appoint a psychiatrist as medical director.
Several studies have shown the effectiveness of psychotherapy assisted by psychedelic drugs, such as LSD and hallucinogenic mushrooms, in treating depression, anxiety and post-traumatic stress disorder, among others.
Patients should be constantly monitored during therapy and medical personnel should immediately report any serious injury or death to the government.
Medical professionals cannot charge drugs, and a qualified professional may only administer them to patients in a medical facility, unless the person is in palliative care.
The press release recalls that outside of In a controlled clinical setting, psychedelic drugs are associated with an increased risk of mental and physical disorders, including anxiety, panic attacks, and self-harm.
In addition, poor dose management can have devastating long-term effects for some people.